Crown Laboratories, Inc. (“Crown”), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings, announce that they have entered into a merger agreement pursuant to which the companies seek to merge the two complementary organizations. Under the terms of the agreement, which has been unanimously approved by Revance’s Board of Directors, Crown will commence a tender offer to acquire all outstanding shares of Revance’s common stock for $6.66 per share in cash, representing a total enterprise value of $924 million.
Read the full article: Crown Laboratories and Revance Announce Entry into Merger Agreement //
Source: https://www.prnewswire.com/news-releases/crown-laboratories-and-revance-announce-entry-into-merger-agreement-302219678.html